Traffic Lights - Latest Updates

Last updated: 15/09/2020

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACETYLCYSTEINE EFFERVESCENT TABLETS (NACYS®) (UPDATED) Green COPD Reduction of sputum viscosity

LMSG Mucolytic prescribing guide

 

AZATHIOPRINE (NEW) Red Generalised Myasthenia gravis
CLONIDINE TRANSDERMAL PATCH (Catapres®) (NEW) Red Hypertension
DELAFLOXACIN MEGLUMINE (Quofenix®) (NEW) Black Acute bacterial skin and skin structure infections

Not yet reviewed

DENOSUMAB (Prolia®) (UPDATED) Amber Full SCA Osteoporosis

Full SCA

Request form

ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (Trikafta®) (NEW) Red Cystic fibrosis as part of managed access programme

Also known as VX-445/VX-661/VX-770

FERRIC MALTOL(Feraccru®) (UPDATED) Amber Simple Iron deficiency anaemia in IBD after at least two failed oral treatment options
FREMANEZUMAB (Ajovy®) (UPDATED) Red Prevention of migraine

In line with NICE TA631

Implementation date 3rd september 2020

KETOTIFEN (NEW) Amber Simple Mast Cell Activation Syndrome (MCAS)
KETOTIFEN UNIT DOSE EYE DROPS (Ketofall®) (NEW) Green Seasonal allergic conjunctivitis

After OTC products have been tried.

LAMOTRIGINE (NEW) Amber Simple Bipolar disorder
LAUROMACROGOL 400 (Aethoxysklerol®) (NEW) Black Sclerotherapy of varicose veins of the lower extremities

Not yet reviewed

LUTROPIN ALFA, FOLLITROPIN ALFA (Pergoveris®) (NEW) Black Stimulation of follicular development

Not yet reviewed

NALOXONE nasal spray (Nyxoid®) (UPDATED) Red Opioid overdose

Turning Point Only

OPICAPONE capsules (Ongentys®) (UPDATED) Amber Simple Parkinson's disease
OSILODROSTAT PHOSPHATE (Isturisa®) (NEW) Black Treatment of endogenous Cushing’s syndrome
REMDESIVIR (Veklury®) (NEW) Red Treatment of coronavirus disease 2019
SEMAGLUTIDE (Rybelsus®) (NEW) Black Treatment of adults with insufficiently controlled type 2 diabetes

Not yet reviewed

TOLCAPONE (NEW) Black Parkinson's disease

For exceptions please see red traffic light

TOLCAPONE (UPDATED) Red Parkinson's disease

For patient’s requiring continuation of treatment after review only

ULIPRISTAL ACETATE (Esmya ®) (UPDATED) Black Uterine fibroids

In line with MHRA alert March 2020 regarding risks of liver injury.

USTEKINUMAB (Stelara®) (NEW) Red Moderate to severe ulcerative colitis

In line with NICE TA633

Implementation date 17th September 2020

VSL#3 (UPDATED) Black Probiotic

Other Updates on this Website

Recent documents from LMSG and TAS


About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more